ES2055175T3 - Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co - Google Patents

Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co

Info

Publication number
ES2055175T3
ES2055175T3 ES90101570T ES90101570T ES2055175T3 ES 2055175 T3 ES2055175 T3 ES 2055175T3 ES 90101570 T ES90101570 T ES 90101570T ES 90101570 T ES90101570 T ES 90101570T ES 2055175 T3 ES2055175 T3 ES 2055175T3
Authority
ES
Spain
Prior art keywords
acid
therapy
preparation
pharmaceutically acceptable
acceptable salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90101570T
Other languages
English (en)
Spanish (es)
Inventor
Grazie Christina Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioresearch SRL
Original Assignee
Bioresearch SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioresearch SRL filed Critical Bioresearch SRL
Application granted granted Critical
Publication of ES2055175T3 publication Critical patent/ES2055175T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES90101570T 1989-01-31 1990-01-26 Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co Expired - Lifetime ES2055175T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8919261A IT1229517B (it) 1989-01-31 1989-01-31 Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.

Publications (1)

Publication Number Publication Date
ES2055175T3 true ES2055175T3 (es) 1994-08-16

Family

ID=11156204

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90101570T Expired - Lifetime ES2055175T3 (es) 1989-01-31 1990-01-26 Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co

Country Status (9)

Country Link
US (1) US5538734A (enExample)
EP (1) EP0382019B1 (enExample)
JP (1) JPH0757727B2 (enExample)
AT (1) ATE88895T1 (enExample)
DE (1) DE69001493T2 (enExample)
DK (1) DK0382019T3 (enExample)
ES (1) ES2055175T3 (enExample)
GR (1) GR3007790T3 (enExample)
IT (1) IT1229517B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
CA2243981C (en) * 1996-01-31 2005-09-06 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
ES2292238T3 (es) * 1998-04-24 2008-03-01 Scarista Limited Tratamiento de la depresion y preparaciones farmaceuticas para el mismo.
EP1102578A4 (en) * 1998-08-03 2005-05-18 Epigenesis Pharmaceuticals Inc NEW ANALGICAL, ANTIINFLAMMATORY AND WOUND HEALING ACTIVE SUBSTANCE
WO2000023089A1 (en) * 1998-10-19 2000-04-27 Merck Patent Gmbh Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid
AU6202299A (en) * 1998-10-30 2000-05-22 Merck Patent Gmbh Compositions for the treatment and prevention of neurological and pathopsychological diseases
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
EP1349554A2 (en) * 2000-12-14 2003-10-08 Tufts University Compositions and methods for treating an arthritic condition
AU2002303427A1 (en) * 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
US20050070487A1 (en) * 2001-04-24 2005-03-31 Nyce Jonathan W. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
JP2005530820A (ja) * 2002-06-17 2005-10-13 エピジェネシス ファーマシューティカルズ リミティド ライアビリティー カンパニー 二水和デヒドロエピアンドロステロン及びその組成物を用いた喘息又は慢性閉塞性肺疾患の治療方法
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
WO2011006147A1 (en) * 2009-07-10 2011-01-13 Scott Iii Linzy O Methods and compositions for treating thyroid-related medical conditions with reduced folates
US8372451B2 (en) * 2010-02-12 2013-02-12 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
WO2018144088A1 (en) 2016-11-03 2018-08-09 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
HUE068578T2 (hu) 2017-03-31 2025-01-28 Merck Patent Gmbh 5-Metil-(6S)-tetrahidrofolsav kristályos nátriumsója

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572137A (en) * 1977-02-22 1980-07-23 Bioresearch Sas Del Dr Livio C Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts
GB2072504B (en) * 1980-03-27 1983-10-26 Coppen A J Pharmaceutical compositions
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8621268D0 (en) * 1986-09-03 1986-10-08 Univ Strathclyde Separation of substances
IT1204612B (it) * 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.

Also Published As

Publication number Publication date
US5538734A (en) 1996-07-23
GR3007790T3 (enExample) 1993-08-31
DK0382019T3 (da) 1993-06-07
IT8919261A0 (it) 1989-01-31
IT1229517B (it) 1991-09-03
DE69001493D1 (de) 1993-06-09
JPH0757727B2 (ja) 1995-06-21
EP0382019B1 (en) 1993-05-05
ATE88895T1 (de) 1993-05-15
JPH02240021A (ja) 1990-09-25
DE69001493T2 (de) 1993-08-26
EP0382019A1 (en) 1990-08-16

Similar Documents

Publication Publication Date Title
ES2055175T3 (es) Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co
ES2084944T3 (es) Amidas terapeuticas.
RU95109100A (ru) Производные ксантина, смесь их изомеров или отдельные изомеры и их фармакологически переносимые соли и фармацевтическая композиция с антагонистической в отношении аденозина активностью на их основе
EP0583482A4 (en) REMEDY FOR INJURY OR HEMORROIDS.
ES2062141T3 (es) Utilizacion de acido 5-metiltetrahidrofolico, acido 5-formiltetrahidrofolico, asi como sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas en forma de liberacion controlada y eficaces en la terapia de trastornos mentales organicos, y las cor
ES2193901T1 (es) Derivados de prostaglandina para el tratamiento de glaucoma o hipertension ocular.
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2055860T3 (es) Derivados 2-aminopirimidinona.
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
ES2091766T3 (es) Uso de n-butil-desoxinojirimicina para el tratamiento de herpes.
MX9400037A (es) Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular.
ES2181165T3 (es) Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
ES2020171T3 (es) Eteres de 1-bencil-3-hidroximetilindazol con 2-hidroxiacidos alifaticos.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
ES2067864T3 (es) Tratamiento de la hipertension ocular con una combinacion sinergica para administracion ocular.
MX9300399A (es) Derivados heterotriciclicos.
ES2031509T3 (es) Un procedimiento para la preparacion de agentes antiarritmicos.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
ATE120180T1 (de) 4,5-dihydroxy und 4,5,8-trihydroxy-9,10-dioxo-2- anthracencarbonsäure-dikohlensäureester und urethane mit therapeutischer wirkung.
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
ES534859A0 (es) Procedimiento para la obtencion de derivados de 1-(4'-alquilsulfonilfenil)-2-amino-1,3-propandiol n-substituidos
ES2059058T3 (es) Combinacion sinergica para uso oftalmico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 382019

Country of ref document: ES